NCT05522387 2026-02-27
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Inmune Bio, Inc.
Phase 2 Terminated
Clinical Trials
9 trialsNCT07189806 2025-09-24
MAPLE-UK
Hvivo
Recruiting
NCT02142959 2025-06-03
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Biogen
Phase 2 Completed
NCT03283826 2024-02-23
EMBOLD
Atara Biotherapeutics
Phase 1/2 Terminated
NCT05321498 2023-09-28
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
Inmune Bio, Inc.
Phase 2 Withdrawn
NCT02500641 2019-06-21
FORWARD
Menarini International Operations Luxembourg SA
Phase 4 Completed
NCT01089998 2013-01-21
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
Life Molecular Imaging SA
Phase 1 Completed
NCT01297088 2013-01-21
PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.
Life Molecular Imaging SA
Phase 1 Completed
NCT00537667 2009-11-26
The SPECTRA Study
Swedish Orphan Biovitrum
Phase 2 Terminated